Drug Profile
Research programme: Fas receptor antagonists - ONL Therapeutics
Alternative Names: Met12; ONL101Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator ONL Therapeutics
- Class Eye disorder therapies; Peptides; Small molecules
- Mechanism of Action CD95 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Glaucoma; Retinal detachment; Retinitis pigmentosa
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Glaucoma in USA (Intravitreous)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in USA (Intravitreous)